The programmed cell death protein 1 (PD-1) is expressed by activated T cells that act as an
immunoregulatory molecule, and are responsible for the negative regulation of T cell …

Despite a decrease in gastric cancer incidence, the development of novel biologic agents
and combined therapeutic strategies, the prognosis of gastric cancer remains poor …

Background Gastric cancer (GC) is one of the most common cancers in Iran. Knowledge of
the epidemiology of the disease is essential in planning for prevention. So this study aimed …

In recent years, immunotherapy has been revolutionized by a new approach that works by
blocking receptors called immune checkpoints (IC). These molecules play a key role in …

Programmed death ligand-1 (PD-L1), which is highly expressed in gastric cancers, interacts
with programmed death-1 (PD-1) on T cells and is involved in T-cell immune resistance. To …

A number of case-control studies regarding the association of the polymorphisms in the
programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) genes with …

This study was intended to determine the efficacy of nivolumab, we evaluated treatment
response with respect to PD-1/PD-L1 SNPs among patients with NSCLC. A total of 50 …

Programmed cell death-1 (PD-1) plays an important inhibitory role in anti-tumor responses,
so it is considered as a powerful candidate gene for individual's genetic susceptibility to …

Polymorphisms in gene encoding programmed death-1 (PD-1) were suggested to be
associated with the risk of multiple cancers. To the best of our knowledge, no investigation …

Background: Although the outcome of patients with gastric cancer (GC) has improved
significantly with the recent implementation of annual screening programs. Reliable …